Machina Capital S.A.S. Invests $1.78 Million in Humana Inc. (NYSE:HUM)

Machina Capital S.A.S. purchased a new position in Humana Inc. (NYSE:HUM - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 6,734 shares of the insurance provider's stock, valued at approximately $1,782,000.

Several other large investors have also recently made changes to their positions in HUM. Dodge & Cox raised its position in shares of Humana by 106.7% in the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after acquiring an additional 5,264,045 shares in the last quarter. Vanguard Group Inc. increased its position in Humana by 15.8% during the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock valued at $3,254,899,000 after buying an additional 1,751,857 shares in the last quarter. Norges Bank acquired a new position in Humana during the 4th quarter valued at about $416,202,000. GAMMA Investing LLC increased its position in Humana by 40,881.1% during the 1st quarter. GAMMA Investing LLC now owns 781,099 shares of the insurance provider's stock valued at $2,066,790,000 after buying an additional 779,193 shares in the last quarter. Finally, Southpoint Capital Advisors LP acquired a new position in Humana during the 4th quarter valued at about $190,282,000. 92.38% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Truist Financial reduced their target price on Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a research report on Wednesday, July 16th. Guggenheim started coverage on Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 target price on the stock. Robert W. Baird lowered their target price on Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research note on Friday. Barclays set a $268.00 price target on Humana and gave the stock an "equal weight" rating in a research report on Thursday, June 12th. Finally, Wells Fargo & Company set a $348.00 price target on Humana in a research report on Friday, July 18th. Sixteen analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $282.43.

Humana Trading Up 3.9%

Shares of HUM traded up $9.01 during midday trading on Friday, hitting $238.22. 1,569,145 shares of the stock were exchanged, compared to its average volume of 1,505,668. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $406.09. The stock has a fifty day simple moving average of $234.56 and a 200 day simple moving average of $256.27. The firm has a market cap of $28.75 billion, a P/E ratio of 16.85, a P/E/G ratio of 1.57 and a beta of 0.44. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.91 and a current ratio of 1.91.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.07 by $1.51. The firm had revenue of $32.11 billion during the quarter, compared to analyst estimates of $32 billion. Humana had a return on equity of 14.47% and a net margin of 1.42%. Humana's revenue was up 8.4% compared to the same quarter last year. During the same period last year, the business posted $7.23 earnings per share. On average, research analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.